MTHFD2L

Across TCGA pan-cancer cohorts, MTHFD2L mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MTHFD2L data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MTHFD2L mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MTHFD2L expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where MTHFD2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.402	0.977	.022	18	view →
GBM	DFS	Median	All	0.831	0.671	.017	4	view →
CCRCC	DFS	Median	All	1.000	0.501	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MTHFD2L–PDAC (OS)

Open the PDAC breakdown →